Featured Research

from universities, journals, and other organizations

Long-Term Outcomes Favor Heart Surgery Over Stents and Angioplasty

Date:
January 29, 2013
Source:
Society of Thoracic Surgeons
Summary:
Patients who undergo coronary artery bypass grafting (CABG) surgery have a lower overall composite risk for heart attack, stroke, and death in the 4 years following the procedure compared to patients who undergo stenting or balloon procedures, according to a new study.

Patients who undergo coronary artery bypass grafting (CABG) surgery have a lower overall composite risk for heart attack, stroke, and death in the 4 years following the procedure compared to patients who undergo stenting or balloon procedures, according to a study released January 29 at the 49th Annual Meeting of The Society of Thoracic Surgeons (STS) held at the Los Angeles Convention Center.

Key Points

• Bypass surgery patients had a lower overall risk for heart attack, stroke, and death than stent or angioplasty patients 4 years following the procedure.

• CABG patients had a lower risk for heart attack while PCI patients had a lower risk for stroke.

• A heart team that includes a cardiac surgeon, cardiologist, and the patient is essential to determine the best treatment.

This study represents phase 2 of the American College of Cardiology (ACC) Foundation/STS Collaboration on the Comparative Effectiveness of Revascularization Strategies (ASCERT) study -- the largest trial to date comparing CABG outcomes to outcomes from coronary stenting or balloon placement, known as percutaneous catheter intervention (PCI).

Fred H. Edwards, MD, Emeritus Professor of Surgery at the University of Florida, Jacksonville, and colleagues analyzed data from nearly 190,000 Medicare patients to compare long-term outcomes from CABG and PCI. In this study, 94% of PCI patients had stent placement and 6% had balloon angioplasty.

"ASCERT showed that in the first few months after the procedure results favored PCI, but long-term data demonstrated a clear overall advantage for CABG. The benefits of CABG progressively increase over time, demonstrating the long-term durability of the procedure," said Dr. Edwards, who is also Director of the STS Research Center.

Collaborating investigators from STS and the ACC used CABG data from the STS National Database and PCI data from the ACC National Cardiovascular Data Registry (NCDR) for patients age 65 and older who underwent revascularization from 2004 through 2007. These data were then linked to information from the Centers for Medicare & Medicaid Services for follow up through 2008.

Phase 1 of ASCERT showed that patients who underwent CABG were 21% less likely to die 4 years after surgery than patients who had PCI. The follow-up study presented here looked at the composite outcomes of heart attack, stroke, and death.

The researchers found that more than 4 years following the procedure, CABG patients had a lower risk for heart attack; PCI patients had a lower risk for stroke -- primarily because of a higher stroke incidence in the first 30 days after CABG treatment; and CABG patients had a 19% lower risk for suffering a composite outcome of stroke, heart attack, and/or death.

Despite a growing number of studies on intervention for stable coronary artery disease that involves several coronary arteries, determining optimal treatment is complicated by evolving technology, differing result interpretations, and variable study designs. ASCERT has helped to clarify and confirm the role of CABG in the treatment of multivessel coronary disease, according to Dr. Edwards.

"While survival is an important consideration, other non-fatal outcomes should be also be considered," said Dr. Edwards. "These new ASCERT results reinforce the need for a 'heart team' approach to ensure that the patient is fully informed of the most likely outcomes when determining the best treatment for multivessel disease. The heart team should include a cardiac surgeon, a cardiologist, and the patient."


Story Source:

The above story is based on materials provided by Society of Thoracic Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

Society of Thoracic Surgeons. "Long-Term Outcomes Favor Heart Surgery Over Stents and Angioplasty." ScienceDaily. ScienceDaily, 29 January 2013. <www.sciencedaily.com/releases/2013/01/130129074422.htm>.
Society of Thoracic Surgeons. (2013, January 29). Long-Term Outcomes Favor Heart Surgery Over Stents and Angioplasty. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2013/01/130129074422.htm
Society of Thoracic Surgeons. "Long-Term Outcomes Favor Heart Surgery Over Stents and Angioplasty." ScienceDaily. www.sciencedaily.com/releases/2013/01/130129074422.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins